Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

Variable CET (n=100) BEV (n=104) P-value
Age at onset (years) 64.2±9.5 64.5±8.7 0.231
CRC locationa, n (%)    0.331
 Left 52 (52.0) 47 (45.2)  
 Right 48 (48.0) 57 (54.8)  
Metastatic sites, n (%)    0.848
 Intra-abdominal 25 (25.0) 27 (26.0)  
 Lung 14 (14.0) 16 (15.4)  
 Bone 22 (22.0) 26 (25.0)  
 Live 25 (25.0) 17 (16.3)  
 Brain 7 (7.0) 9 (8.7)  
 Other 11 (11.0) 1413.5)  
Serum lactate dehydrogenase level, n (%)    0.428
 Normalb 33 (33.0) 29 (27.9)  
 Above normal 67 (67.0) 75 (72.1)  
Portal vein invasion, n (%)    0.733
 Yes 67 (67.0) 72 (69.2)  
 No 33 (33.0) 32 (30.8)  
Duration of treatment (months) 27.2±11.4 27.3±12.5 0.106
Hepatic encephalopathy, n (%) 0 (0.0) 0 (0) 1.000
ECOG PS, n (%)    0.860
 0 43 (43.0) 46 (44.2)  
 1 57 (57.0) 58 (55.8)  
Number of metastatic sites, n (%)    0.454
 3 13 (13.0) 20 (19.2)  
 > 3 72 (72.0) 68 (65.4)  
 Unknown 15 (15.0) 16 (15.4)  
  1. aTumours occurring from the cecum to the transverse colon were considered to be right-sided tumours, and those occurring from the splenic flexure to the sigmoid colon were considered to be left-sided tumours [20]. bUsing continuous monitoring method: female 100-230 U/L. CET Cetuximab, BEV Bevacizumab, CRC Colorectal cancer, ECOG PS Eastern Collaborative Oncology Group performance status
\